Gensaic
Gensaic is a Cambridge-based biotech developing the FORGE Engine, an AI-powered tissue-selective RNA delivery platform, and siRNA therapeutics for cardiometabolic diseases (obesity, MASH, metabolic syndrome), monetized through licensing and co-development partnerships with large pharmaceutical companies.
- Company typePrivate
- Founded2021
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Gensaic does
Gensaic is a privately held biotechnology company developing tissue-specific in vivo delivery systems and multifunctional siRNA constructs for cardiometabolic and metabolic disease. The company's core technology is the FORGE Engine, a five-step integrated platform that (1) screens a diverse library of billions of candidate delivery ligands without prior assumptions to identify tissue-homing variants, (2) applies protein language models trained on deep sequencing datasets to map sequence to function and surface functional ligands, (3) conjugates dual siRNA payloads directly to the delivery ligand for programmable tissue-selective silencing, (4) uses AI to identify dual-gene target combinations for network-level intervention validated in vivo, and (5) applies the resulting constructs to cardiometabolic indications. Gensaic has demonstrated 90% mRNA knockdown in vivo and reports exploring 200+ sequence space units through the platform.
Gensaic's pipeline comprises three therapeutic programs in cardiometabolic disease: the Obesity + Lean Mass program and the Obesity + MASH program, both in lead optimization and targeting adipose and skeletal muscle or adipose and liver tissues respectively, and a Cardiometabolic Disease program in discovery targeting adipose tissue. The company is also pursuing an orthogonal bacteriophage-based gene delivery program for cystic fibrosis under funding from the Cystic Fibrosis Foundation's Quest to a Cure program. The business model centers on platform licensing and co-development partnerships with large pharmaceutical companies — exemplified by a March 2025 collaboration with Novo Nordisk worth up to $354 million in upfront, development, regulatory, and commercial milestones plus royalties for cardiometabolic disease applications. Headquartered at LabCentral 238 in Cambridge, Massachusetts with 11–50 employees, Gensaic operates as a B2B platform company targeting enterprise pharmaceutical partners rather than end consumers.
Gensaic firmographics
Firmographics- Name
- Gensaic
- Legal name
- Gensaic, Inc.
- Website
- https://gensaic.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gensaic is a Cambridge-based biotech developing the FORGE Engine, an AI-powered tissue-selective RNA delivery platform, and siRNA therapeutics for cardiometabolic diseases (obesity, MASH, metabolic syndrome), monetized through licensing and co-development partnerships with large pharmaceutical companies.
- Ownership category
- akta.pro rank
Gensaic industry classification
Industry- Product category
- RNA Therapeutics Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where Gensaic is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Gensaic business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Platform Licensing and Co-development Partnerships: Gensaic generates revenue through strategic partnerships with pharmaceutical companies, licensing its tissue-selective delivery platform and co-developing therapeutic programs. The Novo Nordisk collaboration (up to $354M) represents a milestone and royalty-based model where partners fund development in exchange for access to the technology for specific indications.
- Therapeutic Program Development: Development of proprietary therapeutic programs targeting cardiometabolic diseases (obesity, MASH, heart failure, metabolic syndrome) through to clinical stages, with potential for future product commercialization or additional partnership deals.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Gensaic product offering
Product offeringCore offering
Gensaic develops and licenses the FORGE Engine, an AI-powered tissue-specific in vivo delivery platform that pairs unbiased high-throughput screening of billions of delivery ligand variants with protein language models to discover functional tissue-targeting ligands and conjugate dual siRNA payloads for programmable gene silencing. The platform underpins a proprietary pipeline of therapeutic programs targeting cardiometabolic diseases (obesity with lean mass preservation, MASH, heart failure, and metabolic syndrome) and is monetized through strategic licensing and co-development partnerships with large pharmaceutical companies.
Product overview
Gensaic is a biotechnology company developing a unified platform of tissue-specific in vivo delivery systems and multifunctional siRNA constructs. The core technology is the FORGE Engine, an AI-powered discovery platform comprising five integrated steps: (1) unbiased tissue-targeting screening using diverse ligand libraries, (2) AI-guided discovery via protein language models, (3) siRNA payload conjugation, (4) dual biology targeting for network-level intervention, and (5) cardiometabolic market validation. The FORGE Engine powers the company's therapeutic pipeline of three programs: the Obesity + Lean Mass Program and Obesity + MASH Program (both in lead optimization), and a Cardiometabolic Disease Program (in discovery). The platform enables programmable, tissue-selective delivery of siRNA payloads for treating chronic cardiometabolic diseases including obesity, MASH, heart failure, and metabolic syndrome.
Differentiator
Problem solved
Functional benefit
Products and services
- FORGE Engine
- Obesity + Lean Mass Program
- Obesity + MASH Program
- Cardiometabolic Disease Program
Quantifiable outcome
- 90% mRNA knockdown demonstrated in vivo
- +2 more outcomes
Companies that use Gensaic
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Gensaic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature6 records
Gensaic partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Novo NordiskflagshipGensaic and Novo Nordisk announced a collaboration to develop tissue-targeted therapies for cardiometabolic diseases on March 3, 2025. The deal is worth up to $354 million including upfront, development, regulatory, and commercial milestones plus royalties. The collaboration combines Gensaic's AI-powered tissue-selective delivery platform with Novo Nordisk's therapeutic expertise, aiming to identify novel ligands that enable precise transport of therapeutics beyond the liver for obesity and other cardiometabolic indications.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Gensaic competitors and assessment
Company assessmentDirect peers
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi therapeutics with proprietary tissue-targeted delivery platforms (TRiM and prior technologies), including extrahepatic targeting to muscle, lung, and CNS. Highly comparable to Gensaic's tissue-selective siRNA delivery approach for chronic diseases.
- Dyne Therapeutics: Dyne Therapeutics develops tissue-targeted oligonucleotide therapeutics for muscle and CNS diseases using its FORCE platform. Comparable to Gensaic in pursuing extrahepatic tissue delivery of RNA-based medicines with platform licensing economics.
- Wave Life Sciences: Wave Life Sciences uses its PRISM platform to develop stereopure oligonucleotide therapeutics with CNS and muscle tissue targeting. Comparable to Gensaic as a programmable, tissue-targeted RNA therapeutics company pursuing extrahepatic indications.
- Stoke Therapeutics: Stoke Therapeutics uses its TANGO platform for tissue-specific RNA splicing modulation, focused on CNS and other extrahepatic tissues. Comparable to Gensaic's approach of targeting specific tissues beyond the liver with RNA-based programmable therapeutics.
- Sirnaomics: Sirnaomics develops polypeptide nanoparticle (PNP)-based siRNA delivery for extrahepatic tissues including liver, lung, and tumors. Comparable to Gensaic in pursuing novel delivery platforms for RNAi beyond conventional lipid nanoparticles.
Broad incumbents
- Alnylam Pharmaceuticals: Alnylam is the established RNAi therapeutics leader with multiple approved products (Onpattro, Givlaari, etc.) using GalNAc and LNP delivery. Comparable as the dominant player in RNAi that Gensaic is positioning to differentiate from via extrahepatic tissue targeting.
- Moderna: Moderna is the leading LNP-based mRNA therapeutics company with approved COVID and RSV vaccines. Comparable as the dominant LNP delivery platform player that Gensaic aims to differentiate from via extrahepatic tissue targeting with siRNA payloads.
Emerging players
- Strand Therapeutics: Strand Therapeutics develops self-replicating mRNA therapeutics with tissue-selective expression for oncology and other indications. Comparable as an emerging programmable RNA medicines company with tissue-specific delivery focus.
- Aro Biotherapeutics: Aro Biotherapeutics develops tissue-targeted RNAi and protein therapeutics using Centyrin-based delivery ligands for extrahepatic indications. Comparable to Gensaic's ligand-based tissue-selective delivery approach for siRNA therapeutics.
- Generate Biomedicines: Generate Biomedicines uses generative AI for protein/biological therapeutics design. Comparable as an AI-driven protein/biologics discovery platform, though Gensaic's focus is specifically on delivery ligands for RNAi rather than therapeutic proteins themselves.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Gensaic social profiles
Digital presenceGensaic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gensaic leadership team
Management profileNumber of profiles
Profiles17 records
Gensaic funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gensaic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gensaic
What does Gensaic do?
Gensaic develops and licenses the FORGE Engine, an AI-powered tissue-specific in vivo delivery platform that pairs unbiased high-throughput screening of billions of delivery ligand variants with protein language models to discover functional tissue-targeting ligands and conjugate dual siRNA payloads for programmable gene silencing. The platform underpins a proprietary pipeline of therapeutic programs targeting cardiometabolic diseases (obesity with lean mass preservation, MASH, heart failure, and metabolic syndrome) and is monetized through strategic licensing and co-development partnerships with large pharmaceutical companies.
Is Gensaic a public or private company?
Gensaic is a private company. It is classified as unknown and is currently operating.
When was Gensaic founded?
Gensaic was founded in 2021. It employs 11 to 50 people.
Where is Gensaic based?
Gensaic is headquartered in Cambridge, United States, in the North America region.
How does Gensaic make money?
Two revenue lines are on record. Platform Licensing and Co-development Partnerships are the primary driver. The others are therapeutic Program Development.
Who are Gensaic's main competitors?
Direct peers on record are Arrowhead Pharmaceuticals, Dyne Therapeutics, Wave Life Sciences, Stoke Therapeutics and Sirnaomics. Broad incumbents are Alnylam Pharmaceuticals and Moderna. Emerging players are Strand Therapeutics, Aro Biotherapeutics and Generate Biomedicines.
Does Gensaic have an API?
No public API is recorded for Gensaic.
What industry is Gensaic in?
Gensaic's product category is RNA Therapeutics Platform. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.